Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-07-04
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DIZZINESS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-18 (study day 46.0); relationship: REMOTE
mild
assessed
Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-08-18 (study day 46.0); relationship: REMOTE
mild
assessed
Mild HYPOTENSION — outcome: RECOVERED/RESOLVED; onset 2013-08-28 (study day 56.0); relationship: POSSIBLE
Data queries
No data queries.